-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Transplant in Myeloma: Who, When, and Why?

Program: Education Program
Session: Newly Diagnosed Multiple Myeloma: Many Choices and More Questions
Saturday, December 7, 2024, 2:00 PM-3:15 PM

Aurore Perrot, MD, PhD

CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France; Hématologie, Institut Universitaire du Cancer de Toulouse (IUCT) Oncopole, Toulouse, France; University and Hospital of Toulouse, Toulouse, France

Disclosures: Perrot: GSK: Honoraria; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sanofi: Honoraria, Research Funding; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Amgen: Honoraria; Takeda: Honoraria, Research Funding; Menarini Stemline: Honoraria; Abbvie: Honoraria.

OffLabel Disclosure:

See more of: Newly Diagnosed Multiple Myeloma: Many Choices and More Questions
See more of: Education Program
<< Previous Presentation | Next Presentation >>